首页> 外文期刊>PACE: Pacing and clinical electrophysiology >The Role of Angiotensin Receptor Blockers and/or Angiotensin Converting Enzyme Inhibitors in the Prevention of Atrial Fibrillation in Patients with Cardiovascular Diseases:.
【24h】

The Role of Angiotensin Receptor Blockers and/or Angiotensin Converting Enzyme Inhibitors in the Prevention of Atrial Fibrillation in Patients with Cardiovascular Diseases:.

机译:血管紧张素受体阻滞剂和/或血管紧张素转化酶抑制剂在预防心血管疾病患者房颤中的作用:

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

MADRID, A.H., et al.: The Role of Angiotensin Receptor Blockers and/or Angiotensin Converting Enzyme Inhibitors in the Prevention of Atrial Fibrillation in Patients with Cardiovascular Diseases: Meta-Analysis of Randomized Controlled Clinical Trials. The inhibition of the renin-angiotensin system has demonstrated both experimental and clinical effects in preventing atrial fibrillation. However, there is still uncertainty about the role of these drugs in clinical practice. The objective of this review has been to assess the effects of angiotensin II type-1 receptor blockers (ARBs) and/or angiotensin converting enzyme inhibitors (ACEIs) for preventing atrial fibrillation. We searched the Cochrane controlled Trials Register (Cochrane Library Issue 4, 2002), MEDLINE (January 1980 to November 2003), EMBASE (January 1980 to November 2003) and reference list of articles. We also contacted manufacturers and researchers in the field. Selection criteria: We conducted a meta-analysis of all randomized controlled clinical trials that compared ARBs and/or ACEIs with either placebo or conventional therapy in patients with either hypertension, heart failure, ischemic heart disease, or diabetes mellitus. The pooled outcome was the development of new onset atrial fibrillation. Two reviewers independently assessed trial quality and extracted data. In some cases, the study authors were contacted for additional information. Seven trials involving a total of 24,849 patients were included (11,328 randomized to active therapy and 13,521 to control). There was a significant statistical difference in the pooled development of atrial fibrillation between the treatment and control group. (OR, 0.57; 95% CI, 0.39 to 0.82); test for overall effect z = 2.98 P = 0.003). Treatment with ACEIs/ARBs markedly reduces the risk of development or recurrence of atrial fibrillation. (PACE 2004; 27:1405-1410).
机译:MADRID,A.H.等人:血管紧张素受体阻滞剂和/或血管紧张素转化酶抑制剂在预防心血管疾病患者房颤中的作用:随机对照临床试验的荟萃分析。抑制肾素-血管紧张素系统已证明在预防心房颤动方面具有实验和临床效果。然而,关于这些药物在临床实践中的作用仍存在不确定性。这篇综述的目的是评估血管紧张素II型1受体阻滞剂(ARB)和/或血管紧张素转化酶抑制剂(ACEIs)对预防房颤的作用。我们搜索了Cochrane控制的试验注册簿(Cochrane图书馆第4期,2002年),MEDLINE(1980年1月至2003年11月),EMBASE(1980年1月至2003年11月)和参考文献列表。我们还联系了该领域的制造商和研究人员。选择标准:我们对所有随机对照临床试验进行了荟萃分析,比较了高血压,心衰,缺血性心脏病或糖尿病患者中ARB和/或ACEI与安慰剂或常规疗法的比较。合并的结果是发生新的房颤。两名审稿人独立评估了试验质量并提取了数据。在某些情况下,与研究作者联系以获取更多信息。纳入了七项试验,涉及总共24,849例患者(11,328例随机接受积极治疗,而13,521例作为对照)。在治疗组和对照组之间,房颤合并发展存在显着的统计学差异。 (OR,0.57; 95%CI,0.39至0.82);总体效果检验z = 2.98 P = 0.003)。 ACEI / ARB的治疗显着降低了房颤发生或复发的风险。 (PACE 2004; 27:1405-1410)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号